<DOC>
	<DOCNO>NCT00616733</DOCNO>
	<brief_summary>This 12-week study ass safety , tolerability , pharmacokinetics pharmacodynamics oral CS-0777 patient Multiple Sclerosis .</brief_summary>
	<brief_title>12-week Safety Evaluation Oral CS-0777 Multiple Sclerosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis clinically isolate syndrome relapsing form ( ) MS , base Poser McDonald criterion ( may include patient secondary progressive disease ) Clinical relapse within past 3 year gadolinium enhance lesion brain MRI scan within past 12 month Baseline EDSS score 0 6.5 Female subject sexually active , unless sterile postmenopausal least 1 year , must willing use doublebarrier contraception Primary progressive MS Any medical condition predisposes immunocompromise History malignancy , tuberculosis , invasive fungal infection , herpes zoster infection ( shingle ) , opportunistic infection , current active infection Concurrent diagnosis autoimmune disease ( eg , rheumatoid arthritis lupus ) Treatment cyclophosphamide mitoxantrone within 6 month study initiation Treatment cyclosporine , azathioprine , methotrexate immunosuppressant within 3 month study initiation Treatment interferon beta glatiramer acetate within 2 month study initiation Prior treatment natalizumab rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Multiple sclerosis , relapse , secondary progressive , clinically isolated syndrome , MRI</keyword>
</DOC>